Sponsor Directory

Pfizer clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 10:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

3276

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Phase 2, Radiotherapy-Induced Immune Priming, Elranatamab, Relapsed Refractory Multiple Myeloma (RRMM), Extramedullary Disease in Multiple Myeloma, Paramedullary Disease, PMD
Interventions: Elranatamab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-Small-Cell Lung, ALK-positive Advanced NSCLC, ALK-positive Non-small-cell Lung Cancer, ALK-positive NSCLC
Interventions: lorlatinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Relapsed Refractory Multiple Myeloma (RRMM), Relapsed Refractory Multiple Myeloma
Interventions: elranatamab, Isatuximab SC, Isatuximab SC-OBDS; Drug · Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation
Interventions: Encorafenib Pill, Binimetinib Pill, Nivolumab; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Celiac Disease
Interventions: Ritlecitinib, Placebo, Gluten; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Skin Diseases, Bacterial
Interventions: Tigecycline, ampicillin-sulbactam; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 31
States / cities: Scottsdale, Arizona • Jonesboro, Arkansas • Chula Vista, California + 27 more

Conditions: Lyme Borreliosis
Interventions: VLA15, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 5 Years to 65 Years
Enrollment: 625 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 19
States / cities: Bridgeport, Connecticut • Stamford, Connecticut • Waterbury, Connecticut + 12 more

Conditions: Myositis
Interventions: PF-06823859, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 45
States / cities: Glendale, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 22 more

Conditions: SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome
Interventions: Pfizer-BioNTech COVID-19 mRNA vaccine; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 6 Months and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Myeloma
Interventions: Elranatamab, Iberdomide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 34
States / cities: Coral Gables, Florida • Deerfield Beach, Florida • Doral, Florida + 20 more

Conditions: Metastatic Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Breast Cancer, Locally Advanced Breast Cancer
Interventions: Palazestrant, Ribociclib, Alpelisib, Everolimus, Atirmociclib; Drug
Lead sponsor: Olema Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 14
States / cities: Gilbert, Arizona • San Francisco, California • Aurora, Colorado + 11 more

Conditions: Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma Transitional Cell, Non-muscle Invasive Bladder Cancer, NMIBC
Interventions: Enfortumab vedotin; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 21
States / cities: Gilbert, Arizona • Scottsdale, Arizona • Los Angeles, California + 17 more

About this Pfizer sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where Pfizer is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Pfizer trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Pfizer clinical trials

Filter and sort this sponsor

Live official records

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment

ELISA in Relapsed/Refractory MM

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission

Study Comparing the Safety and Efficacy of Tigecycline With Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Skin Infections

Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

About this Pfizer sponsor directory page